Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile

The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC (Fluorouracil + Epirubicin + Cyclophosphamide) chemotherapy. It also aims to compare the quality of life of patients in the first cycle of AC / FEC chemotherapy with and without PG analysis. Patients will be randomized to undergo PG analysis \[PG group\] versus no PG analysis \[Non-/+PG group\]. Those in the PG group would be offered currently available optimal antiemetic prophylaxis, with or without Olanzapine according to PG outcomes. Those in the Non-PG group would be offered currently available optimal antiemetic prophylaxis.

NCT Number	NCT07455955
Lead Sponsor	Chinese University of Hong Kong
Conditions	Breast Cancer
Enrollment	200 participants
Start Date	2026-03-31
Primary Completion	2027-06-03 (estimated)
Study Completion	2028-07-03 (estimated)
Updated on ClinicalTrials.gov	2026-04-01